RxDoctor Payments Data

Ife Torrence

Family · Richmond, VANPI 1699176115

Payments from drug & device makers

$471in general payments, 2019–2025

Across 16 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$137
  • Biohaven Pharmaceuticals, Inc.$64
  • AbbVie$63
  • Boehringer Ingelheim$50
  • Lilly USA, LLC$42
  • Biohaven Pharmaceutical Holding Company Ltd.$42
  • plus $73 from 3 others

What the payments were for

  • Food & beverage$471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$471 in reported general payments places this provider in the 55th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$18,594
Medicare patients
48
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$98,507
JanuviaSitagliptin Phosphate42$63,500
OzempicSemaglutide55$62,319
MounjaroTirzepatide49$53,633
KerendiaFinerenone32$39,612
RybelsusSemaglutide15$31,488
PercocetOxycodone Hcl/Acetaminophen12$29,602
EliquisApixaban34$29,398
LinzessLinaclotide22$25,905
TrulicityDulaglutide24$25,118
XareltoRivaroxaban16$24,809
FarxigaDapagliflozin Propanediol17$13,208
Repatha SureclickEvolocumab18$11,962
Tresiba Flextouch U-100Insulin Degludec13$10,785
Spiriva HandihalerTiotropium Bromide11$9,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$50$98,50767 claims
Novo NordiskOzempic, Rybelsus$12$93,80770 claims
Lilly USA, LLCMounjaro, Trulicity$42$78,75173 claims
BayerKerendia$20$39,61232 claims
AbbVieLinzess$63$25,90522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,332 family providers in Virginia.

Other family in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →